At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Posiphen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)
In Brief
A Phase 2 clinical trial evaluating Posiphen and Placebo for Alzheimer's Disease. Completed, enrolled 18 participants across 6 sites.
Detailed Summary
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsAlzheimer's Disease Cooperative Study (ADCS)
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionDec 2021
Study CompletionDec 2021
TodayJul 2026
First PostedOct 6, 2016
Enrollment StartMar 2, 2017
Primary CompletionDec 10, 2021
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.7 years ago
Interventions
Posiphendrug
oral solid dosage form capsule
Placebodrug
oral solid dosage form capsule